Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-Analysis

Background. Cardiovascular diseases (CDs), notably coronary artery disease (CAD) due to atherosclerosis, impose substantial global health and economic burdens. Fatty acid-binding proteins (FABPs), including FABP-4, have been recently linked to CDs. This study conducted a systematic review and meta-a...

Full description

Saved in:
Bibliographic Details
Main Authors: Narges Jalilian, Reza Pakzad, Mahdi Shahbazi, Seyyed-Reza Edrisi, Karimeh Haghani, Mohsen Jalilian, Salar Bakhtiyari
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Cardiovascular Therapeutics
Online Access:http://dx.doi.org/10.1155/2023/1092263
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850225822323965952
author Narges Jalilian
Reza Pakzad
Mahdi Shahbazi
Seyyed-Reza Edrisi
Karimeh Haghani
Mohsen Jalilian
Salar Bakhtiyari
author_facet Narges Jalilian
Reza Pakzad
Mahdi Shahbazi
Seyyed-Reza Edrisi
Karimeh Haghani
Mohsen Jalilian
Salar Bakhtiyari
author_sort Narges Jalilian
collection DOAJ
description Background. Cardiovascular diseases (CDs), notably coronary artery disease (CAD) due to atherosclerosis, impose substantial global health and economic burdens. Fatty acid-binding proteins (FABPs), including FABP-4, have been recently linked to CDs. This study conducted a systematic review and meta-analysis to examine FABP-4 levels in CAD and atherosclerosis patients, exploring their potential links to these conditions. Methods. A systematic review and meta-analysis were done based on the PRISMA guideline. The international databases including Medline, Embase, Cochrane Library, Scopus, Web of Science, and UpToDate were searched to find all related studies on the effect of FABP-4 on patients with CAD or atherosclerosis which were published till June 2022 without language restriction. The Cochran’s Q-test and I2 statistic were applied to assess heterogeneity, a random effect model was used to estimate the pooled standardized mean difference (SMD), a metaregression method was utilized to investigate the factors affecting heterogeneity between studies, and Egger’s test was used to assess the publication bias. Results. Of 1051 studies, 9 studies with a sample size of 2327 were included in the systematic review and meta-analysis. The level of circulating FABP-4 in the patient groups was significantly higher than in the control groups (SMD=0.60 (95% CI: 0.30 to 0.91, I2: 91.47%)). The SMD in female and male patients were 0.26 (95% CI: 0.01 to 0.52, I2: 0%) and 0.22 (95% CI: 0.08 to 0.35, I2: 44.7%), respectively. There was considerable heterogeneity between the studies. The countries had a positive relationship with heterogeneity (coefficient=0.29, p<0.001); but BMI, lipid indices, gender, study design, and type of kit had no effect on the heterogeneity. No publication bias was observed (p: 0.137). Conclusion. In summary, this meta-analysis revealed elevated circulating FABP-4 levels in CDs, suggesting its potential as a biomarker for these conditions. Further research is warranted to explore its clinical relevance.
format Article
id doaj-art-5b8d726b5aac4677ab84d655f65d80be
institution OA Journals
issn 1755-5922
language English
publishDate 2023-01-01
publisher Wiley
record_format Article
series Cardiovascular Therapeutics
spelling doaj-art-5b8d726b5aac4677ab84d655f65d80be2025-08-20T02:05:13ZengWileyCardiovascular Therapeutics1755-59222023-01-01202310.1155/2023/1092263Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-AnalysisNarges Jalilian0Reza Pakzad1Mahdi Shahbazi2Seyyed-Reza Edrisi3Karimeh Haghani4Mohsen Jalilian5Salar Bakhtiyari6Department of Medical BiochemistryStudent Research CommitteeDepartment of Medical BiochemistryDepartment of Medical BiochemistryDepartment of Medical BiochemistryDepartment of Health Education and PromotionDepartment of Medical BiochemistryBackground. Cardiovascular diseases (CDs), notably coronary artery disease (CAD) due to atherosclerosis, impose substantial global health and economic burdens. Fatty acid-binding proteins (FABPs), including FABP-4, have been recently linked to CDs. This study conducted a systematic review and meta-analysis to examine FABP-4 levels in CAD and atherosclerosis patients, exploring their potential links to these conditions. Methods. A systematic review and meta-analysis were done based on the PRISMA guideline. The international databases including Medline, Embase, Cochrane Library, Scopus, Web of Science, and UpToDate were searched to find all related studies on the effect of FABP-4 on patients with CAD or atherosclerosis which were published till June 2022 without language restriction. The Cochran’s Q-test and I2 statistic were applied to assess heterogeneity, a random effect model was used to estimate the pooled standardized mean difference (SMD), a metaregression method was utilized to investigate the factors affecting heterogeneity between studies, and Egger’s test was used to assess the publication bias. Results. Of 1051 studies, 9 studies with a sample size of 2327 were included in the systematic review and meta-analysis. The level of circulating FABP-4 in the patient groups was significantly higher than in the control groups (SMD=0.60 (95% CI: 0.30 to 0.91, I2: 91.47%)). The SMD in female and male patients were 0.26 (95% CI: 0.01 to 0.52, I2: 0%) and 0.22 (95% CI: 0.08 to 0.35, I2: 44.7%), respectively. There was considerable heterogeneity between the studies. The countries had a positive relationship with heterogeneity (coefficient=0.29, p<0.001); but BMI, lipid indices, gender, study design, and type of kit had no effect on the heterogeneity. No publication bias was observed (p: 0.137). Conclusion. In summary, this meta-analysis revealed elevated circulating FABP-4 levels in CDs, suggesting its potential as a biomarker for these conditions. Further research is warranted to explore its clinical relevance.http://dx.doi.org/10.1155/2023/1092263
spellingShingle Narges Jalilian
Reza Pakzad
Mahdi Shahbazi
Seyyed-Reza Edrisi
Karimeh Haghani
Mohsen Jalilian
Salar Bakhtiyari
Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-Analysis
Cardiovascular Therapeutics
title Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-Analysis
title_full Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-Analysis
title_fullStr Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-Analysis
title_full_unstemmed Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-Analysis
title_short Circulating FABP-4 Levels in Patients with Atherosclerosis or Coronary Artery Disease: A Comprehensive Systematic Review and Meta-Analysis
title_sort circulating fabp 4 levels in patients with atherosclerosis or coronary artery disease a comprehensive systematic review and meta analysis
url http://dx.doi.org/10.1155/2023/1092263
work_keys_str_mv AT nargesjalilian circulatingfabp4levelsinpatientswithatherosclerosisorcoronaryarterydiseaseacomprehensivesystematicreviewandmetaanalysis
AT rezapakzad circulatingfabp4levelsinpatientswithatherosclerosisorcoronaryarterydiseaseacomprehensivesystematicreviewandmetaanalysis
AT mahdishahbazi circulatingfabp4levelsinpatientswithatherosclerosisorcoronaryarterydiseaseacomprehensivesystematicreviewandmetaanalysis
AT seyyedrezaedrisi circulatingfabp4levelsinpatientswithatherosclerosisorcoronaryarterydiseaseacomprehensivesystematicreviewandmetaanalysis
AT karimehhaghani circulatingfabp4levelsinpatientswithatherosclerosisorcoronaryarterydiseaseacomprehensivesystematicreviewandmetaanalysis
AT mohsenjalilian circulatingfabp4levelsinpatientswithatherosclerosisorcoronaryarterydiseaseacomprehensivesystematicreviewandmetaanalysis
AT salarbakhtiyari circulatingfabp4levelsinpatientswithatherosclerosisorcoronaryarterydiseaseacomprehensivesystematicreviewandmetaanalysis